Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis

A Multicenter, Single-arm, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetics of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatitis

This is a multi-center, single arm, open-label study to evaluate safety in children patients with moderate-to severe atopic dermatis.

Inclusion Criteria:

• With atopic dermatis.
• Voluntarily sign the informed consent form.

Exclusion Criteria:

• Any major surgery planned during the research period.
• With intestinal parasitic infection within the first 6 months of screening.
• With any previous malignant tumors prior to screening.
• With any circumstance that is not suitable to participate in this study.